Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
| Autor: | Chris N. Barnes, David L. Bourdet, Srikanth Pendyala, Marie T. Borin, Arthur Lo |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
COPD
medicine.medical_specialty business.industry Cmax Renal function General Medicine medicine.disease Gastroenterology 03 medical and health sciences Liver disease 0302 clinical medicine 030228 respiratory system Pharmacokinetics Internal medicine medicine Potency 030212 general & internal medicine Adverse effect business Kidney disease |
| Zdroj: | International Journal of Chronic Obstructive Pulmonary Disease. 14:2305-2318 |
| ISSN: | 1178-2005 |
| Popis: | Purpose Revefenacin, a long-acting muscarinic antagonist for nebulization, has been shown to improve lung function in patients with chronic obstructive pulmonary disease. Here we report pharmacokinetic (PK) and safety results from two multicenter, open-label, single-dose trials evaluating revefenacin in subjects with severe renal impairment (NCT02578082) and moderate hepatic impairment (NCT02581592). Subjects and methods The renal impairment trial enrolled subjects with normal renal function and severe renal impairment (estimated glomerular filtration rate |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|